

FOI REF: 21/531

1st November 2021

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following questions:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

• Afatinib	1
• Alectinib	0
• Atezolizumab monotherapy	2
• Atezolizumab with chemotherapy	0
• Bevacizumab	0
• Brigatinib	0
• Ceritinib	0
• Crizotinib	0
• Dacomitinib	0
• Dabrafenib with Trametinib	0
• Docetaxel monotherapy or combination with Carboplatin/Cisplatin	0
• Durvalumab	0
• Erlotinib	0
• Gefitinib	0
• Gemcitabine	1
• Lorlatinib	0
• Nintedanib with Docetaxel	0
• Nivolumab	0
• Osimertinib	10
• Paclitaxel	0
• Pembrolizumab monotherapy	8
• Pembrolizumab with chemotherapy	3
• Pemetrexed with Carboplatin/Cisplatin	6
• Vinorelbine with Carboplatin/Cisplatin	1
• Any other active systemic anti-cancer therapy (SACT)	7
• Palliative care only Please see below.	

Cont.../

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this part of your request would significantly exceed the above limit as it would take a manual trawl of individual patient records.

Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

• Atezolizumab monotherapy	1
• Atezolizumab with chemotherapy	0
• Durvalumab	0
• Gemcitabine	0
• Nivolumab	0
• Osimertinib	0
• Paclitaxel	0
• Pembrolizumab (Keytruda) Mono	3
• Pembrolizumab (Keytruda) with Chemotherapy	2
• Other active systemic anti-cancer therapy (SACT)	2
• Palliative care only As above we apply Section 12(1) to this part of your request for the same reason.	

Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

We are currently not participating in any ongoing clinical trials for the treatment of NSCLC.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net